2020 has been a difficult year for everyone. However, despite the many challenges, we can also look back on some milestone achievements. In our latest newsletter, we review some of our major highlights. Click the link to read our newsletter: http://bit.ly/3njT6nQ
Would you like to receive our next newsletter in your email? You can subscribe here: https://www.tricals.org/subscribe-to-our-newsletter/
We look forward to the new year in which we will undoubtedly achieve even more together. Together we will build our highway towards new therapies for ALS.
Related news
TRICALS consensus statement on Tofersen
OPINION: The consensus view of TRICALS neurologists is that Tofersen shows clear […]
The ATLAS study – A clinical trial for people who want to contribute to SOD1-ALS research
Biogen is conducting a clinical trial to evaluate the efficacy and safety […]
Food and Drug Administration (FDA) approves AMX0035 (Amylyx) for the American market
During a meeting of the FDA’S Peripheral and Central Nervous System Drugs […]
Measuring treatment effects based on patient preference
To evaluate the effect of an investigational drug in ALS clinical trials, […]